Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

  1. Willasch, Andre ORCID logo
  2. Peters, Christina ORCID logo
  3. Sedláček, Petr
  4. dalle, jean-hugues ORCID logo
  5. Kitra-Roussou, Vassiliki
  6. Yesilipek, Akif
  7. Wachowiak, Jacek
  8. Lankester, Arjan
  9. Prete, Arcangelo
  10. Hamidieh, Amir Ali
  11. Ifversen, Marianne
  12. Buechner, Jochen ORCID logo
  13. Kriván, Gergely
  14. Hamladji, Rose-Marie
  15. Diaz de Heredia, Cristina ORCID logo
  16. Skorobogatova, Elena
  17. Michel, Gérard
  18. Locatelli, Franco
  19. Bertaina, Alice
  20. Veys, Paul
  21. Dupont, Sophie
  22. Or, Reuven
  23. Güngör, Tayfun ORCID logo
  24. Aleinikova, Olga
  25. Sufliarska, Sabina
  26. Sundin, Mikael
  27. Rascon, Jelena ORCID logo
  28. Kaare, Ain ORCID logo
  29. Nemet, Damir
  30. FAGIOLI, FRANCA ORCID logo
  31. Klingebiel, Thomas Erich
  32. Styczynski, Jan ORCID logo
  33. Bierings, Marc
  34. Nagy, Kálmán
  35. Abecasis, Manuel
  36. Afanasyev, Boris
  37. Ansari, Marc
  38. Vettenranta, Kim
  39. Alseraihy, Amal
  40. Chybicka, Alicja
  41. Robinson, Stephen
  42. Bertrand, Yves
  43. Kupesiz, Alphan
  44. Ghavamzadeh, Ardeshir
  45. Campos, Antonio
  46. Pichler, Herbert ORCID logo
  47. Dalissier, Arnaud
  48. Labopin, Myriam
  49. Corbacioglu, Selim
  50. Balduzzi, Adriana Cristina ORCID logo
  51. GALIMARD, Jacques-Emmanuel ORCID logo
  52. Bader, Peter

Download
s41409-020-0854-0.pdf 1,22MB
WeightNameValue
1000 Titel
  • Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
1000 Autor/in
  1. Willasch, Andre |
  2. Peters, Christina |
  3. Sedláček, Petr |
  4. dalle, jean-hugues |
  5. Kitra-Roussou, Vassiliki |
  6. Yesilipek, Akif |
  7. Wachowiak, Jacek |
  8. Lankester, Arjan |
  9. Prete, Arcangelo |
  10. Hamidieh, Amir Ali |
  11. Ifversen, Marianne |
  12. Buechner, Jochen |
  13. Kriván, Gergely |
  14. Hamladji, Rose-Marie |
  15. Diaz de Heredia, Cristina |
  16. Skorobogatova, Elena |
  17. Michel, Gérard |
  18. Locatelli, Franco |
  19. Bertaina, Alice |
  20. Veys, Paul |
  21. Dupont, Sophie |
  22. Or, Reuven |
  23. Güngör, Tayfun |
  24. Aleinikova, Olga |
  25. Sufliarska, Sabina |
  26. Sundin, Mikael |
  27. Rascon, Jelena |
  28. Kaare, Ain |
  29. Nemet, Damir |
  30. FAGIOLI, FRANCA |
  31. Klingebiel, Thomas Erich |
  32. Styczynski, Jan |
  33. Bierings, Marc |
  34. Nagy, Kálmán |
  35. Abecasis, Manuel |
  36. Afanasyev, Boris |
  37. Ansari, Marc |
  38. Vettenranta, Kim |
  39. Alseraihy, Amal |
  40. Chybicka, Alicja |
  41. Robinson, Stephen |
  42. Bertrand, Yves |
  43. Kupesiz, Alphan |
  44. Ghavamzadeh, Ardeshir |
  45. Campos, Antonio |
  46. Pichler, Herbert |
  47. Dalissier, Arnaud |
  48. Labopin, Myriam |
  49. Corbacioglu, Selim |
  50. Balduzzi, Adriana Cristina |
  51. GALIMARD, Jacques-Emmanuel |
  52. Bader, Peter |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-17
1000 Erschienen in
1000 Quellenangabe
  • 55(8):1540-1551
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41409-020-0854-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376634/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2-18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective 'real-world-practice' study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.
1000 Sacherschließung
lokal Transplantation Conditioning [MeSH]
lokal Humans [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Survival Analysis [MeSH]
lokal Retrospective Studies [MeSH]
lokal Whole-Body Irradiation [MeSH]
lokal Acute lymphocytic leukaemia
lokal Stem-cell research
lokal Article
lokal Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy [MeSH]
lokal Child [MeSH]
lokal Leukemia, Myeloid, Acute [MeSH]
lokal Transplantation, Homologous [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-6798-8998|https://orcid.org/0000-0003-0369-8515|https://frl.publisso.de/adhoc/uri/U2VkbMOhxI1laywgUGV0cg==|https://orcid.org/0000-0002-8406-0793|https://frl.publisso.de/adhoc/uri/S2l0cmEtUm91c3NvdSwgVmFzc2lsaWtp|https://frl.publisso.de/adhoc/uri/WWVzaWxpcGVrLCBBa2lm|https://frl.publisso.de/adhoc/uri/V2FjaG93aWFrLCBKYWNlaw==|https://frl.publisso.de/adhoc/uri/TGFua2VzdGVyLCBBcmphbg==|https://frl.publisso.de/adhoc/uri/UHJldGUsIEFyY2FuZ2Vsbw==|https://frl.publisso.de/adhoc/uri/SGFtaWRpZWgsIEFtaXIgQWxp|https://frl.publisso.de/adhoc/uri/SWZ2ZXJzZW4sIE1hcmlhbm5l|https://orcid.org/0000-0001-5848-4501|https://frl.publisso.de/adhoc/uri/S3JpdsOhbiwgR2VyZ2VseQ==|https://frl.publisso.de/adhoc/uri/SGFtbGFkamksIFJvc2UtTWFyaWU=|https://orcid.org/0000-0001-8086-296X|https://frl.publisso.de/adhoc/uri/U2tvcm9ib2dhdG92YSwgRWxlbmE=|https://frl.publisso.de/adhoc/uri/TWljaGVsLCBHw6lyYXJk|https://frl.publisso.de/adhoc/uri/TG9jYXRlbGxpLCBGcmFuY28=|https://frl.publisso.de/adhoc/uri/QmVydGFpbmEsIEFsaWNl|https://frl.publisso.de/adhoc/uri/VmV5cywgUGF1bA==|https://frl.publisso.de/adhoc/uri/RHVwb250LCBTb3BoaWU=|https://frl.publisso.de/adhoc/uri/T3IsIFJldXZlbg==|https://orcid.org/0000-0002-3261-1186|https://frl.publisso.de/adhoc/uri/QWxlaW5pa292YSwgT2xnYQ==|https://frl.publisso.de/adhoc/uri/U3VmbGlhcnNrYSwgU2FiaW5h|https://frl.publisso.de/adhoc/uri/U3VuZGluLCBNaWthZWw=|https://orcid.org/0000-0003-4420-6943|https://orcid.org/0000-0002-3170-1016|https://frl.publisso.de/adhoc/uri/TmVtZXQsIERhbWly|https://orcid.org/0000-0002-9257-900X|https://frl.publisso.de/adhoc/uri/S2xpbmdlYmllbCwgVGhvbWFzIEVyaWNo|https://orcid.org/0000-0002-3158-119X|https://frl.publisso.de/adhoc/uri/QmllcmluZ3MsIE1hcmM=|https://frl.publisso.de/adhoc/uri/TmFneSwgS8OhbG3DoW4=|https://frl.publisso.de/adhoc/uri/QWJlY2FzaXMsIE1hbnVlbA==|https://frl.publisso.de/adhoc/uri/QWZhbmFzeWV2LCBCb3Jpcw==|https://frl.publisso.de/adhoc/uri/QW5zYXJpLCBNYXJj|https://frl.publisso.de/adhoc/uri/VmV0dGVucmFudGEsIEtpbQ==|https://frl.publisso.de/adhoc/uri/QWxzZXJhaWh5LCBBbWFs|https://frl.publisso.de/adhoc/uri/Q2h5Ymlja2EsIEFsaWNqYQ==|https://frl.publisso.de/adhoc/uri/Um9iaW5zb24sIFN0ZXBoZW4=|https://frl.publisso.de/adhoc/uri/QmVydHJhbmQsIFl2ZXM=|https://frl.publisso.de/adhoc/uri/S3VwZXNpeiwgQWxwaGFu|https://frl.publisso.de/adhoc/uri/R2hhdmFtemFkZWgsIEFyZGVzaGly|https://frl.publisso.de/adhoc/uri/Q2FtcG9zLCBBbnRvbmlv|https://orcid.org/0000-0001-5107-5123|https://frl.publisso.de/adhoc/uri/RGFsaXNzaWVyLCBBcm5hdWQ=|https://frl.publisso.de/adhoc/uri/TGFib3BpbiwgTXlyaWFt|https://frl.publisso.de/adhoc/uri/Q29yYmFjaW9nbHUsIFNlbGlt|https://orcid.org/0000-0002-5879-0610|https://orcid.org/0000-0001-9102-4427|https://frl.publisso.de/adhoc/uri/QmFkZXIsIFBldGVy
1000 Hinweis
  • DeepGreen-ID: 30396ee3f2244c5f86f33ef796751c7d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471378.rdf
1000 Erstellt am 2023-11-18T12:50:09.770+0100
1000 Erstellt von 322
1000 beschreibt frl:6471378
1000 Zuletzt bearbeitet Fri Dec 01 14:14:23 CET 2023
1000 Objekt bearb. Fri Dec 01 14:14:23 CET 2023
1000 Vgl. frl:6471378
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471378 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source